Trial Profile
Prevention of HIV1 Mother to Child Transmission Without Nucleoside Analogue Reverse Transcriptase Inhibitors in the Pre-Partum Phase. A Multicenter Randomised Phase II/III Open Label Study With a Group of 100 Pregnant Women Receiving Lopinavir/Ritonavir and a Group of 50 Receiving Lopinavir/Ritonavir Plus Zidovudine and Lamivudine. ANRS 135 Primeva
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Lopinavir/ritonavir (Primary) ; Lamivudine/zidovudine
- Indications HIV-1 infections
- Focus Therapeutic Use
- 12 Jun 2013 Primary endpoint 'Virological-response-rate' has been met.
- 12 Jun 2013 Status changed from active, no longer recruiting to completed.
- 12 Jun 2013 Results published in Clinical Infectious Diseases.